相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium
Doris K. Hansen et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma
Utkarsh Goel et al.
BLOOD CANCER JOURNAL (2023)
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
Thomas Martin et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
Jesus San-Miguel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2023)
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
Paula Rodriguez-Otero et al.
NEW ENGLAND JOURNAL OF MEDICINE (2023)
Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis
Oren Pasvolsky et al.
BONE MARROW TRANSPLANTATION (2022)
Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group
Henrik Gregersen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2022)
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
Meletios A. Dimopoulos et al.
LANCET HAEMATOLOGY (2022)
Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody
Ajai Chari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Teclistamab in Relapsed or Refractory Multiple Myeloma
Philippe Moreau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE
Hartmut Goldschmidt et al.
LEUKEMIA (2021)
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma
Marc-Andrea Baertsch et al.
CANCERS (2021)
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study
Meletios A. Dimopoulos et al.
BLOOD CANCER JOURNAL (2020)
The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma
Kevin C. Miller et al.
BONE MARROW TRANSPLANTATION (2019)
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
Graham H. Jackson et al.
LANCET ONCOLOGY (2019)
The efficacy of salvage autologous stem cell transplant among patients with multiple myeloma who received maintenance therapy post initial transplant
Shivaprasad Manjappa et al.
BONE MARROW TRANSPLANTATION (2018)
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
Meletios A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis
Philip L. McCarthy et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Michel Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms
Tatiana Pazina et al.
ONCOIMMUNOLOGY (2017)
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial
Gordon Cook et al.
LANCET HAEMATOLOGY (2016)
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma
Sergio Giralt et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT
M. Grovdal et al.
BONE MARROW TRANSPLANTATION (2015)
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Sagar Lonial et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways
Balaji Balasa et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2014)
Autologous Stem Cell Transplantation: An Effective Salvage Therapy in Multiple Myeloma
Emilie Lemieux et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT
H-Y Yhim et al.
BONE MARROW TRANSPLANTATION (2013)
Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC
Shauna M. Collins et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Challenges of Guarantee-Time Bias
Anita Giobbie-Hurder et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Michel Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
Philip L. McCarthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
S. Vincent Rajkumar et al.
BLOOD (2011)